Umeå University's logo

umu.sePublikasjoner
Endre søk
Link to record
Permanent link

Direct link
Löfgren Burström, Anna
Alternativa namn
Publikasjoner (10 av 28) Visa alla publikasjoner
Edin, S., Gylling, B., Li, X., Stenberg, Å., Löfgren Burström, A., Zingmark, C., . . . Palmqvist, R. (2024). Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer: possible implications for immunotherapy. British Journal of Cancer, 130
Åpne denne publikasjonen i ny fane eller vindu >>Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer: possible implications for immunotherapy
Vise andre…
2024 (engelsk)Inngår i: British Journal of Cancer, ISSN 0007-0920, E-ISSN 1532-1827, Vol. 130Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: The immune response has important clinical value in colorectal cancer (CRC) in both prognosis and response to immunotherapy. This study aims to explore tumour immune cell infiltration in relation to clinically well-established molecular markers of CRC.

Methods: Multiplex immunohistochemistry and multispectral imaging was used to evaluate tumour infiltration of cytotoxic T cells (CD8+), Th1 cells (T-bet+), T regulatory cells (FoxP3+), B cells (CD20+), and macrophages (CD68+) in a cohort of 257 CRC patients.

Results: We found the expected association between higher immune-cell infiltration and microsatellite instability. Also, whereas BRAF-mutated tumours displayed increased immune-cell infiltration compared to BRAF wild-type tumours, the opposite was seen for KRAS-mutated tumours, differences that were most prominent for cytotoxic T cells and Th1 cells. The opposing relationships of BRAF and KRAS mutations with tumour infiltration of cytotoxic T cells was validated in an independent cohort of 608 CRC patients. A positive prognostic importance of cytotoxic T cells was found in wild-type as well as KRAS and BRAF-mutated CRCs in both cohorts.

Conclusion: A combined evaluation of MSI status, KRAS and BRAF mutational status, and immune infiltration (cytotoxic T cells) may provide important insights to prognosis and response to immunotherapy in CRC.

sted, utgiver, år, opplag, sider
Springer Nature, 2024
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-217735 (URN)10.1038/s41416-023-02483-9 (DOI)001124195700002 ()38040818 (PubMedID)2-s2.0-85178212553 (Scopus ID)
Forskningsfinansiär
Sjöberg FoundationSwedish Cancer SocietyVästerbotten County Council
Tilgjengelig fra: 2023-12-12 Laget: 2023-12-12 Sist oppdatert: 2024-05-07bibliografisk kontrollert
Bodén, S., Harbs, J., Sundkvist, A., Fuchs, K., Myte, R., Gylling, B., . . . van Guelpen, B. (2023). Plasma concentrations of gut hormones acyl ghrelin and peptide YY and subsequent risk of colorectal cancer and molecular tumor subtypes. Cancer Prevention Research, 16(2), 75-87
Åpne denne publikasjonen i ny fane eller vindu >>Plasma concentrations of gut hormones acyl ghrelin and peptide YY and subsequent risk of colorectal cancer and molecular tumor subtypes
Vise andre…
2023 (engelsk)Inngår i: Cancer Prevention Research, ISSN 1940-6207, E-ISSN 1940-6215, Vol. 16, nr 2, s. 75-87Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Obesity and metabolic dysfunction are implicated in colorectal cancer development. Appetite-regulating gut hormones might have a role in colorectal cancer risk. We investigated whether circulating levels of the gut hormones ghrelin (analyzed as acyl ghrelin) and Peptide YY (PYY) were associated with subsequent colorectal cancer risk, including clinical and molecular tumor subtypes. We also provide descriptive data on these hormones in relation to background participant characteristics and metabolic biomarkers. This population-based study included 1,010 matched case-control pairs with a median of 12.3 years of follow-up. Acyl ghrelin and PYY were measured by multiplex immunoassay. Data on KRAS and BRAF mutations and microsatellite instability (MSI) status were available for 704 and 708 cases, respectively. Conditional logistic regression models estimated association to colorectal cancer risk. Partial correlation and linear regression were used to investigate relationships between background and metabolic variables and variation in plasma gut hormone concentrations. Acyl ghrelin was not clearly associated with colorectal cancer risk (multivariable OR per 1 SD increase: 1.11; 95% CI, 1.00-1.23). Positive associations were observed for specific subtypes, in particular BRAF-mutated colorectal cancer and right-sided colon cancer, although with nonsignificant heterogeneity. PYY was not related to colorectal cancer risk (multivariable OR per 1 SD: 1.04; 95% CI, 0.95-1.14) or any tumor subtype. In the control participants, ghrelin was inversely correlated with BMI, and PYY was positively correlated with C-peptide and insulin levels. These findings provide limited support for a possible role for ghrelin in colorectal cancer development, primarily in specific anatomical and molecular tumor subtypes.

PREVENTION RELEVANCE: The findings of this study do not support a major role for the metabolic gut hormones ghrelin and PYY in colorectal cancer development but suggest the possibility of an involvement for ghrelin in specific tumor subtypes. Elucidating subtype-specific risk factors and mechanisms of carcinogenesis may have implications for precision prevention.

sted, utgiver, år, opplag, sider
American Association for Cancer Research, 2023
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-204740 (URN)10.1158/1940-6207.CAPR-22-0325 (DOI)000928164800001 ()36367526 (PubMedID)2-s2.0-85147457884 (Scopus ID)
Forskningsfinansiär
Region VästerbottenUmeå UniversitySwedish Cancer Society, 2017/ 581Swedish Cancer Society, 2014/780Swedish Cancer Society, 2012/0501Cancerforskningsfonden i Norrland, AMP 21-1039Cancerforskningsfonden i Norrland, AMP 20-1015Cancerforskningsfonden i Norrland, AMP 19-984Knut and Alice Wallenberg Foundation
Tilgjengelig fra: 2023-02-22 Laget: 2023-02-22 Sist oppdatert: 2023-09-05bibliografisk kontrollert
Kerdreux, M., Edin, S., Löwenmark, T., Bronnec, V., Löfgren Burström, A., Zingmark, C., . . . Ling, A. (2023). Porphyromonas gingivalis in colorectal cancer and its association to patient prognosis. Journal of Cancer, 14(9), 1479-1485
Åpne denne publikasjonen i ny fane eller vindu >>Porphyromonas gingivalis in colorectal cancer and its association to patient prognosis
Vise andre…
2023 (engelsk)Inngår i: Journal of Cancer, E-ISSN 1837-9664, Vol. 14, nr 9, s. 1479-1485Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Microbiota dysbiosis may affect both the development and progression of colorectal cancer (CRC). Large metagenomic studies have highlighted specific oral bacteria linked to CRC including Porphyromonas gingivalis. Few studies have however analysed the implications of this bacterium in CRC progression and survival. In this study, we investigated the intestinal presence of P. gingivalis by qPCR in both faecal and mucosal samples from two different patient cohorts, including patients with precancerous dysplasia or CRC, as well as controls. P. gingivalis was detected in 2.6-5.3% of CRC patients and significantly different levels of P. gingivalis were found in faeces of CRC patients compared to controls (P = 0.028). Furthermore, an association was found between the presence of P. gingivalis in faeces and tumour tissue (P < 0.001). Our findings further suggested a potential link between mucosal P. gingivalis and tumours of MSI subtype (P = 0.040). Last but not least, patients with faecal P. gingivalis were found to have a significantly decreased cancer-specific survival (P = 0.040). In conclusion, P. gingivalis could be linked to patients with CRC and to a worse patient prognosis. Further studies are needed to elucidate the role of P. gingivalis in CRC pathogenesis.

sted, utgiver, år, opplag, sider
Ivyspring International Publisher, 2023
Emneord
colorectal cancer, microbiota, Porphyromonas gingivalis, survival
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-212270 (URN)10.7150/jca.83395 (DOI)2-s2.0-85164436178 (Scopus ID)
Forskningsfinansiär
Swedish Cancer SocietyRegion VästerbottenSjöberg Foundation
Tilgjengelig fra: 2023-07-20 Laget: 2023-07-20 Sist oppdatert: 2024-01-08bibliografisk kontrollert
Löwenmark, T., Li, X., Löfgren Burström, A., Zingmark, C., Ling, A., Kellgren, T. G., . . . Palmqvist, R. (2022). Parvimonas micra is associated with tumour immune profiles in molecular subtypes of colorectal cancer. Cancer Immunology and Immunotherapy, 71, 2565-2575
Åpne denne publikasjonen i ny fane eller vindu >>Parvimonas micra is associated with tumour immune profiles in molecular subtypes of colorectal cancer
Vise andre…
2022 (engelsk)Inngår i: Cancer Immunology and Immunotherapy, ISSN 0340-7004, E-ISSN 1432-0851, Vol. 71, s. 2565-2575Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

The importance of the tumour microbiome in different aspects of colorectal cancer (CRC) has been increasingly recognised, but many questions remain. The aim of this study was to explore the effect of specific CRC associated microbes on the tumour immune response, which has a considerable prognostic value in CRC. We applied specific qPCR to detect Parvimonas micra and Fusobacterium nucleatum in tumour tissues from an immunologically well-characterised cohort of 69 CRC patients. This cohort included detailed analyses of immune profiles based on flow cytometry and transcriptomics in tumour tissue and blood, along with comprehensive analyses of molecular subtypes. P. micra and F. nucleatum were detected in 24% and 64% of tumour tissues, respectively. We found a significant association of P. micra with high-grade tumours and tumours of CMS1 subtype. F. nucleatum was significantly associated with right-sided tumours, microsatellite instability, and CMS1 tumours. The immunological analyses revealed significant associations of P. micra with activated CD69+ T lymphocytes and increased antigen-presenting HLA-DR+ B lymphocytes. P. micra was also positively associated with M1 and M2 macrophage traits. The impact of P. micra tumour colonisation on the immune response was further assessed using transcriptomics in validation of our findings. No associations were found between F. nucleatum and immune profiles in this study. Our findings support novel associations between P. micra and the immune response in CRC. A better understanding of these interactions might help to identify important predictive and prognostic tools as well as new targets for therapy.

sted, utgiver, år, opplag, sider
Springer, 2022
Emneord
Colorectal cancer, F. nucleatum, Immunity, Mucosal microbiota, P. micra
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-193335 (URN)10.1007/s00262-022-03179-4 (DOI)000770199300001 ()35301576 (PubMedID)2-s2.0-85126450770 (Scopus ID)
Forskningsfinansiär
Cancerforskningsfonden i Norrland, AMP 21-1048Region Västerbotten, VLL-833541Swedish Cancer Society, 20 1271PjF
Tilgjengelig fra: 2022-03-28 Laget: 2022-03-28 Sist oppdatert: 2024-03-26bibliografisk kontrollert
Ekbäck, E., von Knorring, J., Löfgren Burström, A., Hunhammar, D., Dennhag, I., Molin, J. & Henje Blom, E. (2022). Training for Awareness, Resilience and Action (TARA) for medical students: a single-arm mixed methods feasibility study to evaluate TARA as an indicated intervention to prevent mental disorders and stress-related symptoms. BMC Medical Education, 22(1), Article ID 132.
Åpne denne publikasjonen i ny fane eller vindu >>Training for Awareness, Resilience and Action (TARA) for medical students: a single-arm mixed methods feasibility study to evaluate TARA as an indicated intervention to prevent mental disorders and stress-related symptoms
Vise andre…
2022 (engelsk)Inngår i: BMC Medical Education, E-ISSN 1472-6920, Vol. 22, nr 1, artikkel-id 132Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: Medical students have a higher risk for depression, anxiety, stress-related symptoms, burnout, and suicide, and more rarely seek professional help or treatment than the general population. Appeals are being made to address the mental health and resilience of physicians-to-be. The novel program Training for Awareness, Resilience, and Action (TARA) was originally developed to treat depressed adolescents, targeting specific neuroscientific findings in this population. TARA has shown feasibility and preliminary efficacy in clinically depressed adolescents and corresponding brain-changes in mixed community adolescent samples. The present study investigated the feasibility and acceptability of TARA as a potential indicated prevention program for symptoms of depression, anxiety, stress and burnout in Swedish medical students.

Methods: We conducted a single-arm trial with 23 self-selected students in their early semesters of medical school (mean age 25.38 years, 5 males and 18 females), with or without mental disorders. All participants received TARA. Self-reported symptoms of depression, anxiety, perceived stress and psychological inflexibility were collected before (T0) and after the intervention (T1). Qualitative data on the participants’ experiences of TARA were collected in focus-group interviews conducted halfway through the program and upon completion of the program. Individual interviews were also conducted 2 years later. Qualitative content analysis was performed.

Results: The mean attendance rate was 61.22% and the dropout rate was 17.40%. The Child Session Rating Scale administered after every session reflected an overall acceptable content, mean total score 34.99 out of 40.00. Trends towards improvement were seen across all outcome measures, including the Hospital Anxiety and Depression Scale Anxiety (t = 1.13, p = 0.29) and Depression (t = 1.71, p = 0.11) subscales, Perceived Stress Scale (t = 0.67, p = 0.51) and Avoidance and Fusion Questionnaire for youth (t = 1.64, p = 0.10). None of the participants deteriorated markedly during the intervention. Qualitative content analysis resulted in a main theme labeled: “An uncommon meeting-ground for personal empowerment”, with 4 themes; “Acknowledging unmet needs”, “Entering a free zone”, “Feeling connected to oneself and others” and “Expanding self-efficacy”.

Conclusion: TARA is feasible and acceptable in a mixed sample of Swedish medical students. The students’ reports of entering an uncommon meeting-ground for personal empowerment supports effectiveness studies of TARA in this context.

sted, utgiver, år, opplag, sider
BioMed Central (BMC), 2022
Emneord
Anxiety, Depression, Medical students, Mental health, Psychological stress, Qualitative research
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-193011 (URN)10.1186/s12909-022-03122-2 (DOI)000762282000001 ()35227281 (PubMedID)2-s2.0-85125536398 (Scopus ID)
Forskningsfinansiär
Region VästerbottenRegion VästernorrlandThe Kempe Foundations
Tilgjengelig fra: 2022-03-10 Laget: 2022-03-10 Sist oppdatert: 2024-03-27bibliografisk kontrollert
Löwenmark, T., Löfgren Burström, A., Zingmark, C., Ljuslinder, I., Dahlberg, M., Edin, S. & Palmqvist, R. (2022). Tumour colonisation of Parvimonas micra is associated with decreased survival in colorectal cancer patients. Cancers, 14(23), Article ID 5937.
Åpne denne publikasjonen i ny fane eller vindu >>Tumour colonisation of Parvimonas micra is associated with decreased survival in colorectal cancer patients
Vise andre…
2022 (engelsk)Inngår i: Cancers, ISSN 2072-6694, Vol. 14, nr 23, artikkel-id 5937Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Increasing evidence suggests that the gut microbiota may impact colorectal cancer (CRC) development and progression. In this study, the tumour colonisation of two CRC-associated bacteria, Parvimonas micra and Fusobacterium nucleatum, was studied in relation to patient survival in a cohort of 257 CRC patients. Colonisation of P. micra and F. nucleatum was analysed in fresh frozen tumour tissue (n = 112) and in faeces (n = 250) by qPCR. When analysing tumour tissues, both P. micra and F. nucleatum were found to be associated with decreased five-year cancer-specific survival, an association that remained significant in multivariable analysis for P. micra. Furthermore, we found significant associations of high levels of P. micra and F. nucleatum with tumour molecular characteristics, i.e., tumours mutated in BRAFV600E, and tumours of the MSI subtype. The analysis of faecal samples showed weaker associations with prognosis and tumour molecular characteristics. In conclusion, our findings support a novel association of tumour colonisation of P. micra with decreased patient survival. A better understanding of the role of the gut microbiota in CRC might contribute to the advancement of prognostic tools and new targets for therapy.

Emneord
Fusobacterium nucleatum, Parvimonas micra, colorectal cancer, mucosal microbiota, survival
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-202632 (URN)10.3390/cancers14235937 (DOI)000896321500001 ()36497419 (PubMedID)2-s2.0-85143631346 (Scopus ID)
Forskningsfinansiär
Swedish Cancer Society, 20 1271Sjöberg FoundationCancerforskningsfonden i Norrland, LP 22-2318Region Västerbotten
Tilgjengelig fra: 2023-01-12 Laget: 2023-01-12 Sist oppdatert: 2024-03-26bibliografisk kontrollert
Li, X., Larsson, P., Ljuslinder, I., Ling, A., Löfgren Burström, A., Zingmark, C., . . . Palmqvist, R. (2021). A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry. Pathology, Research and Practice, 220, Article ID 153379.
Åpne denne publikasjonen i ny fane eller vindu >>A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry
Vise andre…
2021 (engelsk)Inngår i: Pathology, Research and Practice, ISSN 0344-0338, E-ISSN 1618-0631, Vol. 220, artikkel-id 153379Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Colorectal cancer (CRC) is a heterogeneous disease with different genetic and molecular backgrounds, leading to a diverse patient prognosis and treatment response. Four consensus molecular subtypes (CMS 1–4) have recently been proposed based on transcriptome profiling. A clinically practical immunohistochemistry (IHC) based CMS classifier consisting of the four markers FRMD6, ZEB1, HTR2B, and CDX2 was then demonstrated. However, the IHC-CMS classifier did not distinguish between CMS2 and CMS3 tumours. In this study, we have applied the proposed transcriptome based and IHC-based CMS classifiers in a CRC cohort of 65 patients and found a concordance of 77.5 %. Further, we modified the IHC-CMS classifier by analysing the differentially expressed genes between CMS2 and CMS3 tumours using RNA-sequencing data from the TCGA dataset. The result showed that WNT signalling was among the most upregulated pathways in CMS2 tumours, and the expression level of CTNNB1 (encoding β-catenin), a WNT pathway hallmark, was significantly upregulated (P = 1.15 × 10−6). We therefore introduced nuclear β-catenin staining to the IHC-CMS classifier. Using the modified classifier in our cohort, we found a 71.4 % concordance between the IHC and RNA-sequencing based CMS classifiers. Moreover, β-catenin staining could classify 16 out of the 19 CMS2/3 tumours into CMS2 or CMS3, thereby showing an 84.2 % concordance with the RNA-sequencing-based classifier. In conclusion, we evaluated CMS classifiers based on transcriptome and IHC analysis. We present a modified IHC panel that categorizes CRC tumours into the four CMS groups. To our knowledge, this is the first study using IHC to identify all four CMS groups.

sted, utgiver, år, opplag, sider
Elsevier, 2021
Emneord
Colorectal cancer, Consensus molecular subtypes, Immunohistochemistry, Protein marker panel, β-catenin
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-181731 (URN)10.1016/j.prp.2021.153379 (DOI)000636762500008 ()2-s2.0-85102316134 (Scopus ID)
Tilgjengelig fra: 2021-03-23 Laget: 2021-03-23 Sist oppdatert: 2023-09-05bibliografisk kontrollert
Li, X., Ling, A., Kellgren, T. G., Lundholm, M., Löfgren Burström, A., Zingmark, C., . . . Edin, S. (2020). A Detailed Flow Cytometric Analysis of Immune Activity Profiles in Molecular Subtypes of Colorectal Cancer. Cancers, 12(11), Article ID 3440.
Åpne denne publikasjonen i ny fane eller vindu >>A Detailed Flow Cytometric Analysis of Immune Activity Profiles in Molecular Subtypes of Colorectal Cancer
Vise andre…
2020 (engelsk)Inngår i: Cancers, ISSN 2072-6694, Vol. 12, nr 11, artikkel-id 3440Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

The local anti-tumour immune response has important prognostic value in colorectal cancer (CRC). In the era of immunotherapy, a better understanding of the immune response in molecular subgroups of CRC may lead to significant advances in personalised medicine. On this note, microsatellite instable (MSI) tumours have been characterised by increased immune infiltration, suggesting MSI as a marker for immune inhibitor checkpoint therapy. Here, we used flow cytometry to perform a comprehensive analysis of immune activity profiles in tumour tissues, adjacent non-malignant tissues and blood, from a cohort of 69 CRC patients. We found several signs of immune suppression in tumours compared to adjacent non-malignant tissues, including T cells more often expressing the immune checkpoint molecules programmed cell death protein (PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4). We further analysed immune cell infiltration in molecular subgroups of CRC. MSI tumours were indeed found to be associated with increased immune infiltration, including increased fractions of PD-1+ T cells. No correlation was, however, found between MSI and the fraction of CTLA-4+ T cells. Interestingly, within the group of patients with microsatellite stable (MSS) tumours, some also presented with increased immune infiltration, including comparably high portions of PD-1+ T cells, but also CTLA-4+ T cells. Furthermore, no correlation was found between PD-1+ and CTLA-4+ T cells, suggesting that different tumours may, to some extent, be regulated by different immune checkpoints. We further evaluated the distribution of immune activity profiles in the consensus molecular subtypes of CRC. In conclusion, our findings suggest that different immune checkpoint inhibitors may be beneficial for selected CRC patients irrespective of MSI status. Improved predictive tools are required to identify these patients.

sted, utgiver, år, opplag, sider
MDPI, 2020
Emneord
colorectal cancer, immune activity profile, microsatellite instability, consensus molecular subtypes
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-177781 (URN)10.3390/cancers12113440 (DOI)000593599000001 ()33228141 (PubMedID)2-s2.0-85096455525 (Scopus ID)
Tilgjengelig fra: 2020-12-22 Laget: 2020-12-22 Sist oppdatert: 2023-03-23bibliografisk kontrollert
Myte, R., Harlid, S., Sundkvist, A., Gylling, B., Häggström, J., Zingmark, C., . . . van Guelpen, B. (2020). A longitudinal study of prediagnostic metabolic biomarkers and the risk of molecular subtypes of colorectal cancer. Scientific Reports, 10(1), Article ID 5336.
Åpne denne publikasjonen i ny fane eller vindu >>A longitudinal study of prediagnostic metabolic biomarkers and the risk of molecular subtypes of colorectal cancer
Vise andre…
2020 (engelsk)Inngår i: Scientific Reports, E-ISSN 2045-2322, Vol. 10, nr 1, artikkel-id 5336Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Body fatness increases the risk of colorectal cancer (CRC). Insulin resistance and altered adipokines are potential mechanisms, but previous biomarker studies have been inconsistent. Intertumoral heterogeneity might provide an explanation. We investigated insulin, C-peptide, adiponectin, and leptin in relation to CRC molecular subtypes using a nested case-control design (1010 cases, 1010 matched controls, median 12.3 years from baseline to CRC diagnosis) from the population-based Northern Sweden Health and Disease Study. Repeated samples were available from 518 participants. Risks of CRC and subtypes, defined by tumor BRAF and KRAS mutations and microsatellite instability (MSI) status, were estimated using conditional logistic regression and linear mixed models. Higher C-peptide and lower adiponectin were associated with increased CRC risk (odds ratios per standard deviation increase (95% CI): 1.11 (1.01, 1.23) and 0.91 (0.83, 1.00), respectively), though weakened when adjusted for body mass index. Insulin and leptin were not associated with CRC risk. Within-individual time trajectories were similar in cases and controls, and no subtype-specific relationships were identified (all Pheterogeneity > 0.1). Adiponectin was weakly inversely associated with the risk of KRAS-mutated (P = 0.08) but not BRAF-mutated or KRAS/BRAF-wildtype CRC, consistent with the one previous study. These findings contribute to an increased understanding of the complex role of body size in CRC.

sted, utgiver, år, opplag, sider
Nature Publishing Group, 2020
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-175075 (URN)10.1038/s41598-020-62129-1 (DOI)000563370200027 ()32210264 (PubMedID)2-s2.0-85082314181 (Scopus ID)
Forskningsfinansiär
Swedish Cancer Society, 2017/581Swedish Cancer Society, 2014/780Swedish Cancer Society, 2012/0501
Tilgjengelig fra: 2020-09-24 Laget: 2020-09-24 Sist oppdatert: 2023-03-24bibliografisk kontrollert
Bodén, S., Myte, R., Harbs, J., Sundkvist, A., Zingmark, C., Löfgren Burström, A., . . . van Guelpen, B. (2020). C-reactive Protein and Future Risk of Clinical and Molecular Subtypes of Colorectal Cancer. Cancer Epidemiology, Biomarkers and Prevention, 29(7), 1482-1491
Åpne denne publikasjonen i ny fane eller vindu >>C-reactive Protein and Future Risk of Clinical and Molecular Subtypes of Colorectal Cancer
Vise andre…
2020 (engelsk)Inngår i: Cancer Epidemiology, Biomarkers and Prevention, ISSN 1055-9965, E-ISSN 1538-7755, Vol. 29, nr 7, s. 1482-1491Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: Inflammation has been implicated in colorectal cancer etiology, but the relationship between C-reactive protein (CRP) and colorectal cancer risk is unclear. We aimed to investigate the association between prediagnostic plasma CRP concentrations and the risk of clinical and molecular colorectal cancer subtypes.

Methods: We used prospectively collected samples from 1,010 matched colorectal cancer case-control pairs from two population-based cohorts in Northern Sweden, including 259 with repeated samples. Conditional logistic regression and linear mixed models were used to estimate relative risks of colorectal cancer, including subtypes based on BRAF and KRAS mutations, microsatellite instability status, tumor location, stage, lag time, and (using unconditional logistic regression) body mass index.

Results: CRP was not associated with colorectal cancer risk, regardless of clinical or molecular colorectal cancer subtype. For participants with advanced tumors and blood samples <5 years before diagnosis, CRP was associated with higher risk [OR per 1 unit increase in natural logarithm (In) transformed CRP, 1.32; 95% confidence interval (CI), 1.01-1.73]. CRP levels increased over time, but average time trajectories were similar for cases and controls (P-interaction = 0.19).

Conclusions: Our results do not support intertumoral heterogeneity as an explanation for previous inconsistent findings regarding the role of CRP in colorectal cancer etiology. The possible association in the subgroup with advanced tumors and shorter follow-up likely reflects undiagnosed cancer at baseline. Impact: Future efforts to establish the putative role of chronic, low-grade inflammation in colorectal cancer development will need to address the complex relationship between systemic inflammatory factors and tumor microenvironment, and might consider larger biomarker panels than CRP alone.

sted, utgiver, år, opplag, sider
American Association for Cancer Research, 2020
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-174012 (URN)10.1158/1055-9965.EPI-19-1339 (DOI)000552627400026 ()32317300 (PubMedID)2-s2.0-85087470027 (Scopus ID)
Tilgjengelig fra: 2020-08-19 Laget: 2020-08-19 Sist oppdatert: 2023-03-23bibliografisk kontrollert
Organisasjoner